Peter S Talbot

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8852602/publications.pdf

Version: 2024-02-01

257429 361001 2,472 39 24 35 h-index citations g-index papers 39 39 39 3478 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Depression and Suicidality in Patients With Psoriasis and the Role of Psoriatic Arthritis: AÂCross-sectional Study in a Tertiary Setting. Journal of the Academy of Consultation-Liaison Psychiatry, 2022, 63, 372-383.	0.4	12
2	Neuroinflammation as measured by positron emission tomography in patients with recent onset and established schizophrenia: implications for immune pathogenesis. Molecular Psychiatry, 2021, 26, 5398-5406.	7.9	34
3	Dopamine and Glutamate in Antipsychotic-Responsive Compared With Antipsychotic-Nonresponsive Psychosis: A Multicenter Positron Emission Tomography and Magnetic Resonance Spectroscopy Study (STRATA). Schizophrenia Bulletin, 2021, 47, 505-516.	4.3	51
4	Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2020, 34, 3-78.	4.0	259
5	Mental health and dermatology practice in the COVIDâ€19 pandemic. Clinical and Experimental Dermatology, 2020, 45, 816-817.	1.3	9
6	Guidelines for the content and format of PET brain data in publications and archives: A consensus paper. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 1576-1585.	4.3	47
7	Psoriasis and Mental Health Workshop Report: Exploring the Links between Psychosocial Factors, Psoriasis, Neuroinflammation and Cardiovascular Disease Risk. Acta Dermato-Venereologica, 2020, 100, 1-8.	1.3	20
8	Cerebral serotonin transporter measurements with [$<$ sup $>$ 11 $<$ /sup $>$ C]DASB: A review on acquisition and preprocessing across 21 PET centres. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 210-222.	4.3	25
9	Multiple-therapy-resistant major depressive disorder: a clinically important concept. British Journal of Psychiatry, 2018, 212, 274-278.	2.8	28
10	Microglial activation, white matter tract damage, and disability in MS. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e443.	6.0	51
11	Acute and chronic changes in brain activity with deep brain stimulation for refractory depression. Journal of Psychopharmacology, 2018, 32, 430-440.	4.0	21
12	Elevated Translocator Protein in Anterior Cingulate in Major Depression and a Role for Inflammation in Suicidal Thinking: A Positron Emission Tomography Study. Biological Psychiatry, 2018, 83, 61-69.	1.3	266
13	Medication nonadherence in bipolar disorder: a narrative review. Therapeutic Advances in Psychopharmacology, 2018, 8, 349-363.	2.7	105
14	Deep brain stimulation of the periaqueductal gray releases endogenous opioids in humans. Neurolmage, 2017, 146, 833-842.	4.2	58
15	Brain inflammation and psoriasis: a [$<$ sup $>$ 11 $<$ /sup $>$ C]-(R)-PK11195 positron emission tomography study. British Journal of Dermatology, 2016, 175, 1082-1084.	1.5	14
16	In vivo imaging of brain microglial activity in antipsychotic-free and medicated schizophrenia: a [11C](R)-PK11195 positron emission tomography study. Molecular Psychiatry, 2016, 21, 1672-1679.	7.9	82
17	Managing inadequate antidepressant response in depressive illness. British Medical Bulletin, 2015, 115, 183-201.	6.9	17
18	Sustained Recreational Use of Ecstasy Is Associated with Altered Pre and Postsynaptic Markers of Serotonin Transmission in Neocortical Areas: A PET Study with [11C]DASB and [11C]MDL 100907. Neuropsychopharmacology, 2012, 37, 1465-1473.	5.4	55

#	Article	IF	CITATIONS
19	Pre- and Postsynaptic Serotonergic Differences in Males with Extreme Levels of Impulsive Aggression Without Callous Unemotional Traits: A Positron Emission Tomography Study Using 11C-DASB and 11C-MDL100907. Biological Psychiatry, 2012, 72, 1004-1011.	1.3	41
20	Extended characterisation of the serotonin 2A (5-HT2A) receptor-selective PET radiotracer 11C-MDL100907 in humans: Quantitative analysis, test–retest reproducibility, and vulnerability to endogenous 5-HT tone. Neurolmage, 2012, 59, 271-285.	4.2	40
21	Bias in iterative reconstruction of low-statistics PET data: benefits of a resolution model. Physics in Medicine and Biology, 2011, 56, 931-949.	3.0	92
22	Brain Serotonin Transporter Occupancy by Oral Sibutramine Dosed to Steady State: A PET Study Using 11C-DASB in Healthy Humans. Neuropsychopharmacology, 2010, 35, 741-751.	5.4	25
23	Bias in iterative reconstruction of low-statistics PET data: Benefits of a resolution model. , 2009, , .		3
24	Recent development and potential use of $\hat{A}\mu$ - and \hat{I}^2 -opioid receptor ligands in positron emission tomography studies. Drug Development Research, 2006, 67, 890-904.	2.9	9
25	Anterior Cingulate and Subgenual Prefrontal Blood Flow Changes Following Tryptophan Depletion in Healthy Males. Neuropsychopharmacology, 2006, 31, 1757-1767.	5.4	64
26	Rapid Tryptophan Depletion Improves Decision-Making Cognition in Healthy Humans without Affecting Reversal Learning or Set Shifting. Neuropsychopharmacology, 2006, 31, 1519-1525.	5.4	50
27	Effects of reduced endogenous 5-HT on the in vivo binding of the serotonin transporter radioligand 11C-DASB in healthy humans. Synapse, 2005, 55, 164-175.	1.2	81
28	Altered Prefrontal Dopaminergic Function in Chronic Recreational Ketamine Users. American Journal of Psychiatry, 2005, 162 , 2352 - 2359 .	7.2	149
29	Brain Serotonin Transporter Distribution in Subjects With Impulsive Aggressivity: A Positron Emission Study With [¹¹ C]McN 5652. American Journal of Psychiatry, 2005, 162, 915-923.	7.2	246
30	Neuroreceptor Imaging in Psychiatry: Theory and Applications. International Review of Neurobiology, 2005, 67, 385-440.	2.0	15
31	Effects of transient reduction of endogenous 5-HT levels on 11C-DASB and 11C-MDL100907 specific binding: Implications for finding a serotonergic radiotracer vulnerable to endogenous competition in humans. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S717-S717.	4.3	0
32	11C-GR103545, a radiotracer for imaging kappa-opioid receptors in vivo with PET: synthesis and evaluation in baboons. Journal of Nuclear Medicine, 2005, 46, 484-94.	5.0	59
33	The molecular neuroimaging of anxiety disorders. Current Psychiatry Reports, 2004, 6, 274-279.	4.5	20
34	In vivo vulnerability to competition by endogenous dopamine: Comparison of the D2 receptor agonist radiotracer $(-)$ -N-[11C]propyl-norapomorphine ([11C]NPA) with the D2 receptor antagonist radiotracer [11C]-raclopride. Synapse, 2004, 52, 188-208.	1.2	145
35	Effect of amphetamine on [18F]fallypride in vivo binding to D2 receptors in striatal and extrastriatal regions of the primate brain: Single bolus and bolus plus constant infusion studies. Synapse, 2004, 54, 46-63.	1.2	61
36	Comparative evaluation of serotonin transporter radioligands 11C-DASB and 11C-McN 5652 in healthy humans. Journal of Nuclear Medicine, 2004, 45, 682-94.	5.0	114

#	Article	IF	CITATIONS
37	The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development. European Neuropsychopharmacology, 2002, 12, 503-511.	0.7	101
38	The effect of the Covidâ€19 pandemic on illness perceptions of psoriasis and the role of depression: Findings from a crossâ€sectional study. Skin Health and Disease, 0, , .	1.5	1
39	Associations between psoriatic arthritis and mental health among patients with psoriasis: A replication and extension study using the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Skin Health and Disease, 0, , .	1.5	2